Table 1.
Rates of sustained MRD-negativity status in transplant-ineligible NDMM
| MRD negativity (10‒5) | MAIA | ALCYONE* | ||||
|---|---|---|---|---|---|---|
| D-Rd | Rd | P † | D-VMP | VMP | P † | |
| Intention-to-treat | n = 368 | n = 369 | n = 350 | n = 356 | ||
| MRD-negative status, n (%) | 106 (28.8) | 34 (9.2) | <.0001 | 94 (26.9) | 25 (7.0) | <.0001 |
| ≥6 mo sustained | 55 (14.9) | 16 (4.3) | <.0001 | 55 (15.7) | 16 (4.5) | <.0001 |
| ≥12 mo sustained | 40 (10.9) | 9 (2.4) | <.0001 | 49 (14.0) | 10 (2.8) | <.0001 |
| Complete response or better | n = 182 | n = 100 | n = 160 | n = 90 | ||
| MRD-negative status, n (%) | 106 (58.2) | 34 (34.0) | .0001 | 94 (58.8) | 25 (27.8) | <.0001 |
| ≥6 mo sustained | 55 (30.2) | 16 (16.0) | .0097 | 55 (34.4) | 16 (17.8) | .0055 |
| ≥12 mo sustained | 40 (22.0) | 9 (9.0) | .0053 | 49 (30.6) | 10 (11.1) | .0006 |
*
MRD data on durability from the ITT population of ALCYONE were reported previously.11
†
P value was calculated using Fisher's exact test.